Recombinant interleukin 2 (IL-2) promotes T cell line-mediated neuroautoimmune disease.
Autoimmunity is dependent on a delicate balance of cellular interactions preventing activation of autoaggressive T cells. Possible side effects of therapeutically injected recombinant interleukins on latent or overt autoimmune disease are uncertain. Using a T cell transfer model of autoimmune central nervous system (CNS) disease, we investigated the in vivo effect of recombinant IL-2. We observed that recombinant IL-2 strongly promotes autoimmune disease.
D000818:Animals; D002460:Cell Line; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced*; D006168:Guinea Pigs; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects*
D007376:Interleukin-2; D011994:Recombinant Proteins